All articles by Cameron Lockwood

Variations on an IRP theme: How payers are repurposing pricing policies for new categories of medicines

"Don't reinvent the wheel." "If it ain't broke, don't fix it." These are adages as old as time. And they…
Taking the pulse of international reference pricing

What a difference a year (or two) makes. When we published the 2017 edition of our International Reference Pricing Guidebook,…
Population health outcomes of American patients under different drug access conditions

As policy-makers examine a range of options to address concerns about high drug prices in the United States, many are…
2018 ISPOR Europe research on IRP

On Tuesday, we presented research at the ISPOR Europe meeting in Barcelona by Cameron Lockwood. The research looks at how…
IRP rumblings: An eclipse of traditional market access strategy?

In the lead up to the solar eclipse next week, it seems fitting to probe a bit further on the…

IRP is dead, long live IRP

International reference pricing (IRP) has been used extensively by policymakers around the world to regulate pharmaceutical prices. In the current…
Pharmaceutical pricing reform efforts in California: Poking the bear in the Grizzly State

It may still be winter, but not all bears are hibernating. In California, Senator Ed Hernandez (D-West Covina), chair of…
The Access to Medicine Index 2016: Highlighting the role for tiered pricing

In the wake of the US presidential election results, let us not forget another important set of results released this…
20 kilobases closer: A course correction for molecular diagnostics in Germany

The field of advanced molecular diagnostics, including next-generation sequencing (NGS), has had a complicated history in Germany. When we performed research on…
Launch in the time of cost containment: How are European countries positioned to fund emerging breakthroughs in oncology?

French President François Hollande pledged in March to raise the issue of high medicines prices at the upcoming meeting of…

Sections